Best Gas Utility Stocks To Own For 2015

NICOSIA, Cyprus (AP) -- A draft bailout document between Cyprus and its international creditors shows that the size of the country's banking sector has been sharply reduced since the country's rescue package was agreed last month.

The draft memorandum of understanding, seen by The Associated Press Wednesday, claims the country's banking sector is now three-and-a-half times the size of the country's economy, down from five-and-a-half times. The new figure is placed in brackets, indicating that it could change further before the memorandum is finalized.

Cyprus' outsized financial institutions were one of the main reasons the country sought a 10 billion euro ($13.04 billion) bailout. As part of the rescue, Cyprus agreed to break up No. 2 bank Laiki, and impose losses on savers with more than 100,000 euros in another lender, the Bank of Cyprus.

Before it is implemented, the memorandum has to be agreed by the 17 eurozone finance ministers and International Monetary Fund and then voted on by several countries' parliaments.

Hot Beverage Stocks To Buy For 2016: iShares Morningstar Small-Cap Value ETF (JKL)

iShares Morningstar Small Value Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Morningstar Small Value Index (the Index). The Index measures the performance of stocks issued by small-capitalization companies that have exhibited value characteristics as determined by Morningstar, Inc.'s (Morningstar) index methodology. Index constituents are drawn from the pool of liquid, United States-domiciled stocks that trade publicly on the NYSE, the AMEX or NASDAQ.

The Morningstar index methodology defines small-capitalization stocks as those stocks that form the 7% of market capitalization between the 90th and 97th percentile of the market capitalization of the stocks eligible to be included in the Morningstar US Market Index (a market index that represents approximately 97% of the market capitalization of publicly traded United States stocks). The Fund uses a representative sampling strategy in seeking to track the Index.

Advisors' Opinion:

• [By Todd Shriber, ETF Professor]

  Unusual volume (at least 5X ADV): QuantShares US Market Neutral Anti-Beta ETF (NYSE: BTAL), iShares 10+ Year Credit Bond ETF (NYSE: CLY), iShares Morningstar Small Value ETF (NYSE: JKL) and the PowerShares Dynamic Energy ETF (NYSE: PXI).

Best Gas Utility Stocks To Own For 2015: Adamis Pharmaceuticals Corp (ADMP)

Adamis Pharmaceuticals Corporation (Adamis), formerly Cellegy Pharmaceuticals, Inc., incorporated on April 22, 2004, operates through its wholly owned subsidiaries Cellegy Holdings, Inc., Adamis Corporation and Biosyn, Inc. Adamis Corporation has two wholly owned subsidiaries: Adamis Viral Therapies, Inc. (Adamis Viral) and Adamis Laboratories, Inc. (Adamis Labs). Adamis Labs is a specialty pharmaceutical company. The Company focuses on the development of preventive and therapeutic vaccine products and cancer drugs for patients with unmet medical needs. Adamis focuses on developing and commercializing products in the anti-inflammatory, allergy and respiratory field that are commercialized by the Company. Additional product candidates in its allergy and respiratory product pipeline include a steroid HFA (hydrofluoroalkane) metered dose inhaler product, referred to as APC-1000, for asthma and chronic obstructive pulmonary disease (COPD); a generic High-functioning autism (HFA) bronchodilator, referred to as APC-2000; and an HFA pressurized metered dose nasal steroid for the treatment of seasonal and perennial allergic rhinitis, referred to as APC-3000.

Adamis Labs��product pipeline includes the single dose-epinephrine PFS syringe product and an inhaled nasal steroid product candidate, and additional asthma and allergy products. Adamis Labs is developing an aerosolized inhaled nasal steroid product, which it referred to as APC-3000, for the treatment of seasonal and perennial allergic rhinitis. The Company�� Adamis Viral subsidiary is focused on the development of Adamis��therapeutic vaccine product candidates and prostate cancer drugs for prostate cancer patients.

Drug Product Candidates in Development

APC-100 is an anti-inflammatory drug candidate. In animal studies, APC-100 demonstrated potent anti-androgenic and anti-inflammatory activities against prostate tumors growing in animal models and showed a safety profile in preclinical safety studies. APC-100! has demonstrated pharmacological characteristics as an oral or injectable anti-inflammatory and anti-androgenic drug candidate with multiple mechanisms of action. APC-100 decreases secretion of human Prostate Specific Antigen (PSA), by human prostate cancer cells growing in mice and also increases the time-to-tumor progression and survival of PCa mice with CS-PCa and CR-PCa tumors.

APC-200 is a drug candidate for both castrate-sensitive and castrate resistant prostate cancer. APC-200 blocks androgen-induced hydrogen peroxide production and inflammation and inhibits mouse PCa. In animal studies, APC-200 was an inhibitor of chronic inflammation, also completely inhibiting oxidase mediated high rates of hydrogen peroxide. APC-200 is developed as an oral drug, specifically in appropriate formulations for patients with PCa.

APC-300 is a multi-targeted small molecule therapeutic drug, which demonstrates anti-inflammatory, pro-apoptotic anti-cancer activities for prostate cancer patients, including men with metastatic CR-PCa. In pre-clinical in vivo studies conducted, APC-300 demonstrated the ability to inhibit human tumor growth and kill both castrate-sensitive and castrate-resistant human prostate cancer tumors. It also decreased human tumor volumes and suppressed local metastasis in human xenograft models, where malignant human prostate or human melanoma tumor tissue was grafted onto athymic immunosuppressed experimental mice. APC-300 inhibited human androgen receptor protein production in these studies. It also inhibited PSA secretion by human PCa cells, which is a serum marker for human prostate cancer.

The Company competes with Medivation, TEVA Pharmaceutical Industries Ltd and AstraZeneca.

Advisors' Opinion:

• [By Bryan Murphy]

  Although the market seems to be losing traction, and even losing ground now, the same can't be said of every single stock. A handful of stocks like China Jo-Jo Drugstores Inc. (NASDAQ:CJJD), Vuzix Corp. (OTCBB:VUZI), and Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) are forging ahead, doling out gains against the grain. Not that moving higher while other names are moving lower is a sure sign that ADMP, VUZI, and CJJD will remain in their uptrends indefinitely, but it sure doesn't hurt their odds. Here's a closer look at each one and why you'd want to add them to your watchlist.

Best Gas Utility Stocks To Own For 2015: Altisource Residential Corp (RESI)

Altisource Residential Corporation is a development-stage company engaged in the acquisition and ownership of single-family rental assets. The Company�� primary sourcing strategy to acquire these assets includes purchase of sub-performing and non-performing mortgages, as well as single-family homes at or following the foreclosure sale (REO Properties (REO)).

The Company intends to pursue opportunities to acquire its single-family rental assets throughout the United States. The Company is managed by Altisource Asset Management Corporation (AAMC). On December 21, 2012, Altisource Residential Corporation�� spin-off from Altisource Portfolio Solutions S.A. (Altisource) was completed.

Advisors' Opinion:

• [By Mark Holder]

  Altisource Residential (NYSE: RESI  ) (NYSE: RESI  ) (NYSE: RESI  ) purchases distressed mortgage loan portfolios with a strategy to work with borrowers to modify and refinance loans to either keep them in their homes or convert the unmodified loans into renovated rental properties.

Best Gas Utility Stocks To Own For 2015: Reliance Steel & Aluminum Co.(RS)

Reliance Steel & Aluminum Co. operates as a metals service center company primarily in the United States and Canada. The company provides metals processing services and distributes a line of approximately 100,000 metal products, including alloy, aluminum, brass, copper, carbon steel, stainless steel, titanium, and specialty steel products to mills and original equipment manufacturers. Its processing services comprise cutting, leveling, sawing, machining, or electropolishing. The company also offers a range of metal perforating and fabrication services; and steel and alloy pipes, tube and bar products, and precision manufacturing of various tools designed for the global energy service companies. Reliance Steel & Aluminum Co. serves manufacturers and end-users in the general manufacturing, non-residential construction, transportation, aerospace, energy, electronics, and semiconductor fabrication and related industries. As of December 31, 2011, it maintained approximately 220 metals service center processing and distribution facilities in the United States, Belgium, Canada, China, Malaysia, Mexico, Singapore, South Korea, the United Arab Emirates, and the United Kingdom. The company was founded in 1939 and is headquartered in Los Angeles, California.

Advisors' Opinion:

• [By Kelley Wright]

  Reliance Steel & Aluminum (RS) is North America's largest metals service company and is looking to get even bigger. The company has increased dividends 20 times since its IPO in 1994, so its designation for outstanding dividend growth is a no-brainer.

• [By Kelley Wright]

  Reliance Steel & Aluminum (RS)��ielding 1.8%.

  The Timely Ten is comprised of stocks from the Undervalued category, based on dividend parameters. They generally have an S&P Dividend & Earnings Quality ranking of A- or better, and show exemplary long-term dividend growth.

• [By Dan Caplinger]

  Reliance Steel & Aluminum (NYSE: RS  ) : up 100%
  The steel industry has been struggling lately, so it's especially remarkable to see Reliance Steel having made not one but two dividend increases in the past year. With increases from $0.15 per share last May to $0.25 in August and then to $0.30 in March, Reliance is bucking the negative trends in steel. What's especially noteworthy is that the company raised its payout even after announcing more than a $750 million deal to buy Metals USA in February -- a move that might have led other companies to rein in its payouts.

• [By Monica Gerson]

  Reliance Steel & Aluminum Co (NYSE: RS) is estimated to report its Q3 earnings at $1.20 per share on revenue of $2.54 billion.

  PulteGroup (NYSE: PHM) is expected to report its Q3 earnings at $0.36 per share on revenue of $1.46 billion.